 |
 |
http://biz.yahoo.com/prnews/980721/ny_diacrin_1.html Tuesday July 21, 8:01 am Eastern Time Company Press Release SOURCE: Diacrin Inc. Diacrin and Massachusetts General Hospital Receive U.S. Patent for Immune System 'Masking' Technology Technology May Allow Cell Transplantation Without Lifelong Immunosuppression Therapy CHARLESTOWN, Mass., July 21, /PRNewswire/ -- Diacrin, Inc. (Nasdaq: DCRN - news) and the Massachusetts General Hospital (MGH) announced today that the United States Patent and Trademark Office has issued Patent No. 5,783,216 to MGH for its ``masking'' technology, a platform process that can camouflage transplanted cells and prevent a patient's immune system from attacking them. Diacrin, to whom MGH has exclusively licensed this breakthrough technology, is currently utilizing it in clinical trials involving the transplantation of porcine brain cells into sufferers of devastating neurological conditions, including Parkinson's disease, Huntington's disease, and focal epilepsy. <SNIP> -- Judith Richards, London, Ontario, Canada [log in to unmask]